The art and science of running a successful pharmaceutical company.
May 6, 2009
By:
Gerhard Symons
Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.
|
April 1, 2009
By:
Joanna Breitstein
From her start as a physician working in apartheid-era South Africa to the dramatic turnaround and takeover of Millennium, Deborah Dunsire has lived a life that has defied all expectations.
|
April 1, 2009
"Best Pharma not Big Pharma" is Merck Serono head Elmar Schnee's business philosophy. He tells Pharm Exec Europe how the Swiss-based company aims to achieve that goal, and points out the current political obstacles.
|
March 1, 2009
By:
Walter Armstrong
Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
|
March 1, 2009
By:
Stephen J. Porth, George P. Sillup
Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety—and the regulators who enforce it.
|
February 4, 2009
By:
George Koroneos, Online Content & News Editor
Facing patent expiry for one of its top drugs and an overabundance of sales staff due to recent acquisitions, King announced that it would eliminate 760 jobs.
|
February 1, 2009
By:
Walter Armstrong
For aiming to be a game-changer in cardiovascular disease, we recognize comeback kid Crestor as the year's No. 1. Plus three fine finalists.
|
February 1, 2009
By:
Joanna Breitstein
The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
|
February 1, 2009
Convert future revenue into present value with alternative approaches to access capital.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
